Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors

BACKGROUND: Management of gastrointestinal stromal tumors (GISTs) has been transformed with tyrosine kinase inhibitors (TKIs). While data on optimal duration of adjuvant imatinib remains elusive, guidelines for administration of neoadjuvant TKIs remain unknown. METHODS: Under an institutional review...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Surg Oncol
Main Authors: Bednarski, Brian K., Araujo, Dejka M., Yi, Min, Torres, Keila E., Lazar, Alexander, Trent, Jonathan C., Cormier, Janice N., Pisters, Peter W. T., Lev, Dina Chelouche, Pollock, Raphael E., Feig, Barry W., Hunt, Kelly K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4524653/
https://ncbi.nlm.nih.gov/pubmed/24639192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-014-3632-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados